Schott Pharma Invests in Sterile Cartridge Production
Schott Pharma, a drug containment and delivery solutions provider, is investing more than €100 million in its existing site in Lukácsháza, Hungary, to expand its capacity for sterile ready-to-use (RTU) cartridges.
Symbolic start of construction: L to R Dr. István Orbán, Director General of Vas County Government Office, Dominique Bauert, Head of Strategic Business Field Sterile Solutions at Schott Pharma, Péter Ágh, Hungarian State Secretary for Construction and Transport, Eva Szabó, Site Manager Lukácsháza, Torsten Derr, CEO Schott AG, Andreas Reisse, CEO Schott Pharma, István Joó, Government Commissioner and CEO Hungarian Investment Promotion Agency (HIPA), Fabian Stöcker, Head of Business Segment Drug Containment Solutions at Schott Pharma, and János Virág, Mayor of Lukácsháza bury time capsule at groundbreaking event.
© Schott Pharma/Péter Benkő
Schott Pharma has expanded its Lukácsháza site with a new facility for prefillable glass syringes, which are used for GLP-1 therapies, vaccines, and biologics. Since opening in June 2024, the site has added 120 employees, begun production, and increased capacity.
With RTU cartridges, the company is now looking to add additional manufacturing capacity for high-value solutions to the site, which has sufficient space to support the company's growth strategy. “We would like to express our sincerest gratitude to the Ministry of Foreign Affairs and Trade for its support of these two expansion projects. Lukácsháza is not only an important location for ensuring supply security to customers in the region but also makes an important contribution to Schott Pharma's global growth strategy,” says Eva Szabó, Site Manager Lukácsháza.The company is adding a high-tech RTU cartridge manufacturing facility at its Lukácsháza site, featuring advanced equipment, automated processes, and new environmental measures. This will be the company’s second site, after St. Gallen, Switzerland, to produce sterile cartridges.
Schott Pharma is investing more than €100 million in its site in Lukácsháza, Hungary, to expand its capacity for sterile cartridges.
© Schott Pharma
